

1 **Serum levels of specialised pro-resolving molecule pathways are greatly**  
2 **increased in SARS-CoV-2 patients and correlate with markers of the**  
3 **adaptive immune response.**

4 James Turnbull<sup>1,2,3,a</sup>, Rakesh Jha<sup>1,2,a</sup>, Catherine A. Ortori<sup>2</sup>, Eleanor Lunt<sup>4</sup>, Patrick  
5 J. Tighe<sup>3</sup>, William L. Irving<sup>1,3</sup>, Sameer A. Gohir<sup>1,6</sup>, Dong-Hyun Kim<sup>2</sup>, Ana M.  
6 Valdes<sup>1,5,6</sup>, Alexander W. Tarr<sup>1,3</sup>, David A. Barrett<sup>1,2</sup>, Victoria Chapman<sup>1,3,5</sup>.

7 <sup>1</sup> NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals  
8 NHS Trust, Nottingham, UK

9 <sup>2</sup> Centre for Analytical Bioscience, Advanced Materials and Healthcare  
10 Technologies Division, School of Pharmacy, University of Nottingham, Nottingham,  
11 UK

12 <sup>3</sup> School of Life Sciences, Faculty of Medicine and Health Sciences, The University  
13 of Nottingham, Nottingham, UK

14 <sup>4</sup> Department of Health Care for Older People (HCOP), Queen's Medical Centre,  
15 Nottingham University Hospitals NHS Trust, Derby Road, Nottingham,  
16 Nottinghamshire NG7 2UH, UK

17 <sup>5</sup> Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK

18 <sup>6</sup> Academic Rheumatology, University of Nottingham, Nottingham, UK

19 <sup>a</sup> Joint First Author

20 **Correspondence:** Professor Victoria Chapman, [mbzvc@exmail.nottingham.ac.uk](mailto:mbzvc@exmail.nottingham.ac.uk)

21 Phone: +44 (0)115 82 30136

22 School of Life Sciences  
23 University of Nottingham  
24 University Park  
25 Nottingham

26 **NOT PEER REVIEWED** Preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **Abstract**  
28

29 **Background**

30 Specialised pro-resolution molecules (SPMs) halt the transition to chronic  
31 pathogenic inflammation. We aimed to quantify serum levels of pro- and anti-  
32 inflammatory bioactive lipids in SARS-CoV-2 patients, and to identify potential  
33 relationships with innate responses and clinical outcome.

34 **Methods**

35 Serum from 50 hospital admitted inpatients (22 female, 28 male) with confirmed  
36 symptomatic SARS-CoV-2 infection and 94 age and sex matched cohort collected  
37 prior to the pandemic, were processed for quantification of bioactive lipids. Anti-  
38 nucleocapsid and anti-spike quantitative binding assays were performed.

39 **Results**

40 SARS-CoV-2 serum had significantly higher concentrations of omega-6 derived  
41 pro-inflammatory lipids and omega-6 and omega-3 derived SPMs, compared to  
42 age and sex matched controls. Levels of SPMs were not markedly altered by age.  
43 There were significant positive correlations between SPMs and other bioactive  
44 lipids and anti-spike antibody binding. Levels of some SPMs were significantly  
45 higher in patients with an anti-spike antibody value  $>0.5$ . Levels of linoleic acid  
46 (LA) and 5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic acid (5,6-DHET) were  
47 significantly lower in SARS-COV-2 patients who died.

48 **Discussion**

49 SARS-COV-2 infection was associated with a robust activation of the pathways  
50 that generate the specialised pro-resolution molecules and other anti-

51 inflammatory bioactive lipids, supporting the future investigation of these  
52 pathways which may inform the development of novel treatments.

53 **Key words:** SARS-CoV-2, specialised pro-resolving molecules, immune  
54 response, bioactive lipids, anti-nucleocapsid

55

## 56 **Introduction**

57 Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is  
58 characterised by fever and cough, with more severe cases developing acute  
59 respiratory distress, acute lung injury, pneumonia, and mortality[1-3]. The higher  
60 rates of severe SARS-CoV-2 illness and death are associated with increasing  
61 age[4, 5]. SARS-CoV-2 infection is associated with changes in adaptive and innate  
62 immunity, including elevated levels of circulating neutrophils and the presence of  
63 peripherally derived macrophages in the lungs of severe cases[6, 7], reduced  
64 numbers of circulating T cells[8] and robust cytokine responses, which continues  
65 after clearance of the virus[9]. SARS-CoV-2 infection is associated with elevated  
66 levels of pro-inflammatory cytokines, including IL6, IL1 $\beta$ , and TNF $\alpha$ [10, 11],  
67 however levels of anti-inflammatory cytokines IL4 and IL10 are also elevated[10].  
68 Knowledge of the impact of SARS-CoV-2 infection on the resolution of  
69 inflammation pathways will provide crucial new mechanistic insight and potential  
70 new avenues for treatment[12-14].

71 Prostaglandins (PGs) and leukotrienes have essential roles in initiating acute  
72 inflammatory responses and the generation of pro-inflammatory cytokines, which  
73 sustain chronic inflammatory responses. In concert with these cyclooxygenase  
74 (COX) pathways, the lipoxygenase (LOX) pathways produce pro-inflammatory  
75 hydroxyeicosatetraenoic acids (HETEs) from arachidonic acid (AA) and  
76 hydroxyoctadecadienoic acids (HODEs) from di-homo- $\gamma$ -linolenic acid (LNA). The  
77 active curtailing of inflammatory signalling is essential to restore tissue  
78 homeostasis and prevent chronic inflammatory events leading to pathology[15].  
79 Following the initial acute inflammatory phase, specialised pro-resolving molecules  
80 (SPMs), derived from key polyunsaturated fatty acids (PUFAs), are generated and

81 orchestrate the resolution of inflammation by promoting macrophage mediated  
82 clearance of cellular debris and counteracting the effects of pro-inflammatory  
83 cytokines[15]. The SPMs are derived from omega-6 ( $\omega$ -6) (LNA, AA) or omega-3  
84 ( $\omega$ -3) (eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)) substrates via  
85 the COX, LOX and cytochrome P450 pathways[15] (SI Figure 1).

86 The most well characterised SPMs are the resolvins (Rvs), protectins (PDs), and  
87 maresins (MaRs), which halt the transition from acute to chronic inflammation  
88 preventing pathogenesis[16]. 17(S)-hydroxy Docosahexaenoic acid (17-HDHA), a  
89 substrate for the generation of the D series resolvins[15], enhances the adaptive  
90 immune response in a preclinical model of influenza[17], both 17-HDHA and  
91 resolvin D1 enhance B cell production and promote B cell differentiation towards  
92 an antibody secreting phenotype[18]). The epoxyeicosatrienoic acids (EETs),  
93 derived from AA via soluble epoxide hydrolase (sEH), also mediate resolution of  
94 inflammation [19, 20], down-regulating inflammatory transcription factors such  
95 as NF- $\kappa$ B [21], curtailing the induction of COX2 and production of cytokines[22].

96 Current knowledge of the consequences of SARS-CoV-2 infection on endogenous  
97 levels of SPMs and EETs is in its infancy. Building a comprehensive picture of the  
98 impact of SARS-CoV-2 infection upon the serum lipidomic profile will aid  
99 understanding of the therapeutic potential of resolution pathways for SARS-COV-  
100 2 infection[12, 13, 23]. Our aims were to 1) compare serum levels of a range of  
101 SPMs and pro-inflammatory bioactive lipids between patients admitted to hospital  
102 with SARS-CoV-2 infection and an age-matched control group, 2) determine the  
103 potential relationship between levels of these bioactive lipids and levels of anti-  
104 nucleocapsid and anti-spike antibody titre, markers of the production of an  
105 adaptive immune response[24] and 3) investigate outcomes following infection.

## 106 **Methods**

### 107 **Sample Collection and Preparation**

108 Serum samples obtained from 50 inpatients admitted to Nottingham University  
109 Hospitals NHS Trust Queen's Medical Centre with symptomatic RT-PCR confirmed  
110 SARS-CoV-2 infection were collected as diagnostic specimens for clinical chemistry  
111 testing, excess sera were provided anonymously for research purposes. Review  
112 by the University of Nottingham's School of Life Sciences Ethical Review  
113 Committee deemed the study to not require full ethical review. Approval for use  
114 of anonymized clinical data was provided by the NHS Health Research Authority  
115 (HRA) and Health and Care Research Wales (HCRW) (ref. 20/HRA/4843). Samples  
116 were determined not to be Relevant Materials in line with the Human Tissue  
117 Authority. Risk assessments were approved by the UK Health and Safety Executive  
118 (ref. CBA1.470.20.1). Serum samples were initially stored at 4°C for 24 h and  
119 then inactivated with the WHO-approved protocol (4-hour room temperature  
120 incubation with 1% Triton X-100 in PBS) before analysis. Detailed methods on the  
121 assessment of the potential effect of the viral deactivation protocol on serum lipid  
122 levels are detailed in the supplementary information. Viral genomic sequencing  
123 of samples from a subset of these patients was performed as part of the COG-UK  
124 consortium[25].

125 Baseline serum samples from the iBEAT-OA cohort study (n=94) were used as age  
126 and sex matched controls[26], which were collected prior to the SARS-CoV-2  
127 pandemic served as a SARS-CoV-2 negative control. As collected pre-pandemic a  
128 lack of SARS-CoV-2 infection was not confirmed. The iBEAT-OA cohort had a  
129 confirmed diagnosis of osteoarthritis. Ethical approval was obtained from the

130 Research Ethics Committee (ref: 18/EM/0154) and the Health Research Authority  
131 (protocol no: 18021).

### 132 **Lipidomic Analysis**

133 Serum bioactive lipids were extracted and measured using our published liquid  
134 chromatography-mass spectrometry (LC-MS/MS) quantification method for the  
135 major classes of pro- and anti-inflammatory lipid molecules, which has been  
136 updated to include SPMs and their precursor molecules[27]. 44 bioactive lipids  
137 were quantified, detailed methods are in Supplementary Information.

### 138 **Anti-Nucleocapsid & Anti-Spike Binding Assays**

139 Anti-nucleocapsid and anti-spike quantitative binding assays were performed on  
140 serum samples using ELISA following the protocol described by Tighe et al  
141 (2020)[24]. Levels of C reactive protein (CRP) were measured in clinical diagnostic  
142 tests (mean 172.9 levels ranged from 11-489). The median time between sample  
143 collection for CRP measurement and collection of serum for the measurement of  
144 bioactive lipids, anti-nucleocapsid and anti-spike antibody binding was 5 days.

### 145 **Data Analysis**

146 GraphPad Prism (Version 8.2.1) was used. In some cases, patients were stratified  
147 into three age groups (<60, 61-74, & >75 years). Groups were assessed for  
148 normal distribution using D'Agostino & Pearson test and evaluated for significant  
149 changes between groups using Kruskal-Wallis test with multiple comparisons  
150 corrected for using Dunn's test. Multivariate analysis using Metaboanalyst 4.0  
151 (<https://www.metaboanalyst.ca/>)[28] including principal component analysis  
152 (PCA) was performed. Partial least square discrimination analysis (PLS-DA) was  
153 used to identify the lipid mediator clusters. A cross validation analysis was used

154 to validate the PLS-DA model based on accuracy, R<sup>2</sup> and Q<sup>2</sup> scores and a  
155 permutation test (SI Figure 3). Variable Importance in Projection (VIP) scores  
156 greater than 1 were recognized as playing a key role in cluster differentiation (SI  
157 Figure 4 & SI Table 1).

158



## 159 **Results**

### 160 **Characteristics of SARS-COV-2 infection cohort and clinical features**

161 Serum samples collected from hospital inpatients (22 female, 28 male) with  
162 confirmed diagnosis of Sars-CoV-2 (SARS-CoV-2) were studied (SI Table 2). 30  
163 patients recovered and were discharged, 20 died, and 25 spent time in ICU during  
164 hospitalisation (SI Table 2).

### 165 **SARS-COV-2 serum has a distinct bioactive lipid profile**

166 SARS-CoV-2 serum had high concentrations of  $\omega$ -6 derived pro-inflammatory  
167 lipids (Table 1) and  $\omega$ -6 and  $\omega$ -3 derived anti-inflammatory SPM lipids (Table 1),  
168 which were significantly increased compared to age and sex matched control  
169 serum. In control serum, comparable to the healthy population, many of the anti-  
170 inflammatory SPM lipids were not detectable, or present at very low levels[29].  
171 PLS-DA analysis of these lipids identified contributors to the separation between  
172 the SARS-CoV-2 and control serum (Figure 1A). 22 lipids from seven classes of  
173 lipids had a VIP score  $>1$  and statistically underpinned the separation between the  
174 two clusters (SI Figure 4A). Although serum concentrations of the PUFAs (LA, EPA  
175 and DHA) were generally not different between the SARS-CoV-2 and control serum  
176 (Figure 1B, SI Table 1), concentrations of the down-stream bioactive lipids were  
177 markedly increased in SARS-CoV-2 serum (Figure 1B). There were substantially  
178 higher levels of the pro-inflammatory molecule PGD<sub>2</sub>, and the anti-inflammatory  
179 SPMs (17-HDHA, RvD<sub>4</sub>, LXA<sub>4</sub>, LXA<sub>5</sub>), endocannabinoids (2-AG, AEA) and, 11,12-  
180 EET in SARS-CoV-2 serum, compared to control serum (Table 1, SI Table 3). Our  
181 findings support a profound mobilisation of pro-resolving mediators following  
182 SARS-CoV-2 infection.

183 PLS-DA analysis revealed a clear separation between the SARS-CoV-2 and control  
184 serum for the three age groups (SI Figure 2A-C). Overall, the majority of the  
185 lipids contributing to the separation between the SARS-CoV-2 and control serum  
186 were the same for the three age groups studied (SI Figure 2D). This was  
187 confirmed by a univariate analysis (Figure 2, SI Table 4). Overall, the ability to  
188 mount a pro-resolution response was not markedly altered by age in our study.

189 Changes in the flux through enzymatic pathways generating SPMs may provide  
190 insight into novel treatments for Sars-CoV-2 infection. Serum levels of DHA and  
191 the downstream metabolites, 17-HDHA and 14-HDHA, were correlated in both  
192 SARS-CoV-2 and control serum (Figure 3A-B). However, levels of EPA and 18-  
193 HEPE were correlated in SARS-CoV-2 serum but not control serum, suggesting a  
194 potential upregulation of the E series resolving pathway following infection (Figure  
195 3C).

196 Serum levels of AA were within a healthy range in the control group[30], but were  
197 elevated in SARS-CoV-2 serum across all age groups (SI Figure 5A, Table 1).  
198 Levels of the anti-inflammatory EETs and the downstream metabolites (DHETs)  
199 are presented both individually and as a ratio to reflect the activity of the sEH  
200 pathway (Table 1). The ratio of 11,12-EET:11,12-DHET was significantly  
201 increased in SARS-CoV-2 serum, compared to matched control serum (SI Figure  
202 5B). There were some differences in the ratios of 8,9-EET:8,9-DHET and 14,15-  
203 EET:14,15-DHET but these were less consistent across the age groups for the two  
204 groups (Table 1). In the SARS-CoV-2 serum, levels of AA were correlated with all  
205 EETs, whereas in the control serum AA was only correlated with 8,9-EET and  
206 11,12-EET (Figure 4B & 4C). These data suggest changes in the flux through the  
207 sEH pathway following SARS-CoV-2 infection, worthy of further future  
208 investigation.

209 **Associations between adaptive immune responses to SARS-COV-2**  
210 **infection and serum levels of bioactive lipids**

211 Anti-SARS-CoV-2 antibody binding to the nucleocapsid protein was interrogated  
212 using a reference antigen. Viral sequence data, where available, confirmed that  
213 the variants circulating in our cohort were either the Hu-1 strain, or the variant  
214 defining the 20B lineage (defined by the spike D614G variant), with no variability  
215 in nucleocapsid amino acid sequence[24]. There was a range of levels of anti-  
216 nucleocapsid (0.15 to 3.11 OD450) and anti-spike antibody (0.115-3.067 OD450)  
217 in the SARS-CoV-2 group. Anti-nucleocapsid data (Table 2) are discussed in SI.  
218 Based on the range of anti-spike antibody binding, patients were separated into  
219 two groups: low (<0.5, n=26) and high (>0.5, n=26), the subset of patients who  
220 died had significantly lower levels of anti-spike antibody binding (SI Figure 6).  
221 Levels of 18-HEPE, 17-HDHA, RvD4 and 14,15-EET were significantly higher in  
222 patients with an anti-spike antibody value >0.5 (Figure 5). There were statistically  
223 significant positive correlations between these lipids and anti-spike antibody  
224 binding for the entire group of patients (Table 2).

225 Analysis of serum levels of bioactive lipids early in the infection and the clinical  
226 outcome identified that levels of LA and 5,6-DHET were significantly lower in  
227 SARS-CoV-2 infected patients who died, and the ratio of 5,6-EET:5,6-DHET was  
228 higher in those patients that died compared to those that survived (SI Table 5).

229

## 230 **Discussion**

231 SARS-CoV-2 infection was associated with robust increases in both  $\omega$ -6 and  $\omega$ -3  
232 derived bioactive lipids which have well characterized roles in both pro- and anti-  
233 inflammatory responses[31]. Significant increases in serum levels of pro-  
234 inflammatory lipids included PGE<sub>2</sub>, TBXB<sub>2</sub> and LTB<sub>4</sub> and a range of bioactive lipids  
235 with well-established roles in dampening down / resolving inflammatory processes  
236 were evident in the SARS-CoV-2 group, compared to the age matched control  
237 group. Of particular note was the 47-fold increase in levels of the SPM precursor  
238 17-HDHA and the SPMs RvD<sub>4</sub> and Mar<sub>2</sub>, serum levels of which are normally close  
239 to, or below, the limits of detection in the healthy population[32]. Substantial  
240 increases in levels of some EETs and endocannabinoids also support a concerted  
241 anti-inflammatory response via multiple enzymatic pathways following SARS-CoV-  
242 2 infection. Our demonstration of a robust activation of the resolution pathways  
243 following SARS-CoV-2 infection, irrespective of patient age, points to a complex  
244 pathophysiological response which may be amenable to pharmacological  
245 intervention and provide new targets for treatment.

246 There was a broad range of anti-nucleocapsid and anti-spike responses in the  
247 SARS-CoV-2 group, indicative of adaptive immune response to infection.  
248 Consistent with a larger study, increased anti-spike responses were associated  
249 with improved clinical outcome[24]. SARS-CoV-2 patients with higher anti-spike  
250 responses (>0.5) had significantly increased levels of a number anti-inflammatory  
251 and resolution molecules as well as some pro-inflammatory lipids. The statistically  
252 altered bioactive lipids represent clusters of SPMs, lipoxins and EETs which either  
253 directly mediate resolution of inflammation or are metabolites in the resolution  
254 pathways and are generated by COX, LOX and CYP pathways. Levels of PUFA  
255 substrates were not substantially altered by SARS-CoV-2 infection or age, thus it

256 is unlikely that substrate and therefore diet is major determining factor in the  
257 resolution response to SARS-CoV-2 infection. The strong correlations between  
258 PUFAs and their downstream SPM pathway metabolites in the SARS-CoV-2  
259 infection group suggests that these enzymatic pathways are upregulated by this  
260 infection, particularly evident for the E series pathway. Our findings support future  
261 studies of the relationship between the antibody response to SARS-CoV-2  
262 infection, activation of the resolution pathways and clinical outcome in a larger  
263 cohort of patients.

264 Our findings are consistent with the recent report of up-regulation of plasma and  
265 serum SPMs and increased expression of related enzymatic pathways in peripheral  
266 blood monocyte subsets in 19 patients infected with SARS-CoV-2[33] and findings  
267 by Archambault et al (2020)[34]. In addition, increased levels of pro-  
268 inflammatory bioactive lipids and anti-inflammatory SPMs, including RvD4, D5,  
269 D2, D1 and PDX have been reported in bronchoalveolar lavage from SARS-CoV-2  
270 patient[35]. SPMs are already known to modulate acute lung injury and  
271 respiratory distress syndrome[36], supporting these findings following SARS-CoV-  
272 2 infection. Antibodies generated by B cells are critical to anti-viral immunity.  
273 The D series precursors and resolvins, including 17-HDHA, enhance human B cell  
274 antibody production by promoting differentiation towards an anti-body secreting  
275 phenotype[18]. In a pre-clinical murine model of influenza immunization, 17-  
276 HDHA treatment increased antigen specific antibody responses and protected  
277 against live influenza virus infection[17]. These data suggest that a robust  
278 generation of 17-HDHA following infection not only acts to counter pro-  
279 inflammatory responses but may also facilitate the response of B cells to mount  
280 an antibody response. To date there are no studies of the effects of the SPMs on  
281 SARS-CoV-2 infection in patients, however, it has been reported that both RvD1

282 and RvD2 have beneficial effects on inflammatory responses in SARS-CoV-2  
283 infected macrophages[37].

284 Current evidence suggests that treatments for SARS-CoV-2 infection, alongside  
285 vaccinations, will remain a priority in the immediate future. Identification of the  
286 critical steps involved in the up-regulation of these anti-inflammatory pathways  
287 may be instructive for the development of interventions aimed at dampening the  
288 inflammatory response or promoting the clearance of the inflammation arising  
289 from SARS-CoV-2 infection. Dexamethasone has been identified as an important  
290 treatment to promote recovery from SARS-CoV-2 infection. Dexamethasone has  
291 been shown to increase SPM levels in a small number of SARS-CoV-2 infected  
292 patients[33], healthy volunteers[38] and in allergic airway inflammation[39].  
293 Future investigation of the potential contribution of SPMs to the beneficial effects  
294 of dexamethasone in patients with SARS-CoV-2 infection in a larger cohort will  
295 improve further our understanding of the potential mechanisms of action of this  
296 treatment.

297 There are a number of study limitations. Serum samples were collected from  
298 patients hospitalised with SARS-CoV-2 for clinical diagnostic tests during the first  
299 wave of the pandemic in the UK. Due to the clinical pressures within the system  
300 at the time some clinical data, such as BMI, was not collected. It is known that  
301 levels of SPMs are decreased with increased BMI, which could potentially  
302 contribute to SARS-CoV-2 related morbidities and mortalities[40]. Although we  
303 have data relating to whether a patient was admitted to intensive care, clinical  
304 decision making was related to multiple factors beyond the severity of the infection  
305 and therefore further analysis of potential impact has not been performed. Serum  
306 samples were collected within the first few days of hospital admission and  
307 represent a snapshot of the anti-nucleocapsid and anti-spike response and the

308 lipid levels at a point in time. It is important to note that levels of antibodies  
309 change over time, however we do not have matched longitudinal data. The anti-  
310 nucleocapsid and anti-spike signal provides an indication of the potency of the  
311 adaptive immune response following infection. The viral genome sequencing data  
312 available for these patients indicated that the nucleocapsid amino acid sequence  
313 was completely conserved between infections. While it is possible that there may  
314 be mismatches between the antigen used in our assay and the strain of infecting  
315 virus that mean that antibodies are present which are undetected by our assay,  
316 at the time of sampling there was minimal genetic diversity in UK  
317 isolates[[www.nextstrain.org](http://www.nextstrain.org)]. To mitigate against this, we used ELISAs against  
318 two antigens.

319 In summary, our findings highlight that SARS-CoV-2 infection can lead to very  
320 robust activation of the pathways that generate the specialised pro-resolving  
321 molecules and other anti-inflammatory bioactive lipids. This new knowledge  
322 supports the future investigation of these pathways which may inform the  
323 development of novel anti-inflammatory treatments for SARS-CoV-2 infection.  
324 Furthermore, these new datasets provide us opportunities to explore further the  
325 underlying molecular pathways that regulate the resolution pathways in humans,  
326 with the goal of identifying novel approaches for the development of new  
327 therapeutics for other infections and chronic inflammatory diseases.

328

329 **Notes**

330 **Author Contributions:**

331 VC, DAB, DHK, & AWT conceived the study, secured the funding, supervised data  
332 collection and analysis, and prepared manuscript.

333 JT, RJ, & CO performed lipidomic analysis of samples.

334 AWT, PJT, & WLI supplied clinical samples, performed measurement of anti-  
335 nucleocapsid and prepared manuscript.

336 AMV & SAG provided control serum samples.

337 JT & RJ performed statistical analysis and prepared manuscript.

338 EL provided clinical insight into data interpretation and prepared manuscript.

339 All authors reviewed manuscript and had final responsibility for the decision to  
340 submit for publication.

341 **Acknowledgements:**

342 The authors thank Professors David Walsh and John Gladman for their advice in  
343 preparation of the manuscript. The authors also thank Dr Divyateja Hrushikesh  
344 and colleagues from the Queens Medical Centre for providing samples and clinical  
345 data.

346 **Disclaimer:**

347 The source of funding had no influence over the design or conduct of the study.

348 **Financial Support:**



349 This research was funded by the NIHR Nottingham Biomedical Research Centre.

350 The views expressed are those of the author(s) and not necessarily those of the

351 NHS, the NIHR or the Department of Health and Social Care.

352 **Potential conflicts of interest:** The authors declare no conflicts of interests.

353

395 **References**

- 396 1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill  
397 patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,  
398 retrospective, observational study. *The Lancet Respiratory Medicine*  
399 **2020**; 8(5): 475-81.
- 400 2. Fan E, Beitler JR, Brochard L, et al. COVID-19-associated acute  
401 respiratory distress syndrome: is a different approach to management  
402 warranted? *The Lancet Respiratory Medicine* **2020**; 8(8): 816-21.
- 403 3. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory  
404 Distress Syndrome and Death in Patients With Coronavirus Disease 2019  
405 Pneumonia in Wuhan, China. *JAMA Intern Med* **2020**; 180(7): 934-43.
- 406 4. Ho FK, Petermann-Rocha F, Gray SR, et al. Is older age associated with  
407 COVID-19 mortality in the absence of other risk factors? General  
408 population cohort study of 470,034 participants. *PloS one* **2020**; 15(11):  
409 e0241824-e.
- 410 5. Jayaraj R, Kumarasamy C, Shetty SS, Ram M R, Shaw P. Clinical and  
411 conceptual comments on "Risk factors of critical & mortal COVID-19  
412 cases: A systematic literature review and meta-analysis". *The Journal of*  
413 *infection* **2020**; 81(4): 647-79.
- 414 6. Merad M, Martin JC. Pathological inflammation in patients with COVID-19:  
415 a key role for monocytes and macrophages. *Nature reviews Immunology*  
416 **2020**; 20(6): 355-62.
- 417 7. Zhand S, Saghaeian Jazi M, Mohammadi S, et al. COVID-19: The Immune  
418 Responses and Clinical Therapy Candidates. *International journal of*  
419 *molecular sciences* **2020**; 21(15): 5559.

- 420 8. Kenneth ER, Monty M, David AS, et al. Severe immunosuppression and  
421 not a cytokine storm characterizes COVID-19 infections. JCI insight **2021**;  
422 5(17).
- 423 9. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, et al. Imbalanced Host  
424 Response to SARS-CoV-2 Drives Development of COVID-19. Cell  
425 (Cambridge) **2020**; 181(5): 1036-45.e9.
- 426 10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with  
427 2019 novel coronavirus in Wuhan, China. The Lancet (British edition)  
428 **2020**; 395(10223): 497-506.
- 429 11. Karaba SM, Jones G, Helsel T, et al. Prevalence of Co-infection at the Time  
430 of Hospital Admission in COVID-19 Patients, A Multicenter Study. Open  
431 forum infectious diseases **2021**; 8(1): ofaa578-ofaa.
- 432 12. Regidor P-A, Santos FG, Rizo JM, Egea FM. Pro resolving inflammatory  
433 effects of the lipid mediators of omega 3 fatty acids and its implication in  
434 SARS COVID-19. Medical hypotheses **2020**; 145: 110340-.
- 435 13. Panigrahy D, Gilligan MM, Huang S, et al. Inflammation resolution: a dual-  
436 pronged approach to averting cytokine storms in COVID-19? Cancer and  
437 metastasis reviews **2020**; 39(2): 337-40.
- 438 14. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19:  
439 The Current Evidence and Treatment Strategies. Frontiers in immunology  
440 **2020**; 11: 1708-.
- 441 15. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-  
442 resolving superfamily of mediators. The Journal of clinical investigation  
443 **2018**; 128(7): 2657-69.

- 444 16. Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous  
445 regulators of infection and inflammation. *Nature reviews Immunology*  
446 **2016**; 16(1): 51-67.
- 447 17. Ramon S, Baker SF, Sahler JM, et al. The specialized proresolving  
448 mediator 17-HDHA enhances the antibody-mediated immune response  
449 against influenza virus: a new class of adjuvant? *The Journal of*  
450 *immunology (1950)* **2014**; 193(12): 6031-40.
- 451 18. Ramon S, Gao F, Serhan CN, Phipps RP. Specialized proresolving  
452 mediators enhance human B cell differentiation to antibody-secreting  
453 cells. *The Journal of immunology (1950)* **2012**; 189(2): 1036-42.
- 454 19. Tam Vincent C, Quehenberger O, Oshansky Christine M, et al. Lipidomic  
455 Profiling of Influenza Infection Identifies Mediators that Induce and  
456 Resolve Inflammation. *Cell (Cambridge)* **2013**; 154(1): 213-27.
- 457 20. Romashko M, Schragenheim J, Abraham NG, McClung JA.  
458 Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic  
459 Cardiomyopathy. *Trends in pharmacological sciences (Regular ed)* **2016**;  
460 37(11): 945-62.
- 461 21. Dong L, Dong L, Zhou Y, et al. Soluble Epoxide Hydrolase Inhibitor  
462 Suppresses the Expression of Triggering Receptor Expressed on Myeloid  
463 Cells-1 by Inhibiting NF-kB Activation in Murine Macrophage.  
464 *Inflammation* **2017**; 40(1): 13-20.
- 465 22. Bora I, Steven LJ, Arzu U, et al. Soluble Epoxide Hydrolase and  
466 Epoxyeicosatrienoic Acids Modulate Two Distinct Analgesic Pathways.  
467 *Proceedings of the National Academy of Sciences - PNAS* **2008**; 105(48):  
468 18901-6.

- 469 23. Darwesh AM, Bassiouni W, Sosnowski D, Seubert JM. Can N-3  
470 polyunsaturated fatty acids be considered a potential adjuvant therapy for  
471 COVID-19-associated cardiovascular complications? *Pharmacology &*  
472 *therapeutics (Oxford)* **2020**: 107703-.
- 473 24. Tighe PJ, Urbanowicz RA, Fairclough CL, et al. **2020**.
- 474 25. consortium TC-GUC-U. An integrated national scale SARS-CoV-2 genomic  
475 surveillance network. *The Lancet Microbe* **2020**; 1(3): e99-e100.
- 476 26. Gohir SA, Greenhaff P, Abhishek A, Valdes AM. Evaluating the efficacy of  
477 Internet-Based Exercise programme Aimed at Treating knee Osteoarthritis  
478 (iBEAT-OA) in the community: a study protocol for a randomised  
479 controlled trial. *BMJ open* **2019**; 9(10): e030564-e.
- 480 27. Wong A, Sagar DR, Ortori CA, Kendall DA, Chapman V, Barrett DA.  
481 Simultaneous tissue profiling of eicosanoid and endocannabinoid lipid  
482 families in a rat model of osteoarthritis. *Journal of lipid research* **2014**;  
483 55(9): 1902-13.
- 484 28. Chong J, Xia J. Using MetaboAnalyst 4.0 for Metabolomics Data Analysis,  
485 Interpretation, and Integration with Other Omics Data. *Computational*  
486 *Methods and Data Analysis for Metabolomics* **2020**; 2104: 337-60.
- 487 29. Norris PC, Skulas-Ray AC, Riley I, et al. Identification of specialized pro-  
488 resolving mediator clusters from healthy adults after intravenous low-dose  
489 endotoxin and omega-3 supplementation: a methodological validation.  
490 *Scientific reports* **2018**; 8(1): 18050-13.
- 491 30. Abdelmagid SA, Clarke SE, Nielsen DE, et al. Correction: Comprehensive  
492 profiling of plasma fatty acid concentrations in young healthy Canadian  
493 adults. *PloS one* **2015**; 10(5): e0128167-e.

- 494 31. Gilroy DW, Bishop-Bailey D. Lipid mediators in immune regulation and  
495 resolution. *British journal of pharmacology* **2019**; 176(8): 1009-23.
- 496 32. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and  
497 signature profiles for pro-resolving and inflammatory lipid mediators in  
498 human tissue. *American Journal of Physiology: Cell Physiology* **2014**;  
499 307(1): C39-C54.
- 500 33. Koenis DS, Beegun I, Jouvène CC, et al. Disrupted Resolution Mechanisms  
501 Favor Altered Phagocyte Responses in Covid-19. *Circulation research*  
502 **2021**.
- 503 34. Archambault AS, Zaid Y, Rakotoarivelo V, et al. High levels of eicosanoids  
504 and docosanoids in the lungs of intubated COVID-19 patients. *The FASEB*  
505 *journal* **2021**; 35(6): e21666-n/a.
- 506 35. Schwarz B, Sharma L, Roberts L, et al. Severe SARS-CoV-2 infection in  
507 humans is defined by a shift in the serum lipidome resulting in  
508 dysregulation of eicosanoid immune mediators. *medRxiv* **2020**.
- 509 36. Sandhaus S, Swick AG. Specialized proresolving mediators in infection and  
510 lung injury. *BioFactors (Oxford)* **2021**; 47(1): 6-18.
- 511 37. Recchiuti A, Patrino S, Mattoscio D, et al. Resolvin D1 and D2 reduce  
512 SARS-CoV-2-induced inflammatory responses in cystic fibrosis  
513 macrophages. *The FASEB journal* **2021**; 35(4): e21441-n/a.
- 514 38. Barden A, Phillips M, Hill LM, et al. Antiemetic doses of dexamethasone  
515 and their effects on immune cell populations and plasma mediators of  
516 inflammation resolution in healthy volunteers. *Prostaglandins,*  
517 *leukotrienes and essential fatty acids* **2018**; 139: 31-9.
- 518 39. Pyrillou K, Chairakaki A-D, Tamvakopoulos C, Andreakos E.  
519 Dexamethasone induces  $\omega$ 3-derived immunoresolvents driving resolution

520 of allergic airway inflammation. *Journal of allergy and clinical immunology*  
521 **2018**; 142(2): 691-5.e4.

522 40. Pal A, Gowdy KM, Oestreich KJ, Beck M, Shaikh SR. Obesity-Driven  
523 Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse  
524 Outcomes During SARS-CoV-2 Infection. *Frontiers in immunology* **2020**;  
525 11: 1997.

## 526 **Figure Legends:**

527 **Figure 1.** A: Partial least square discrimination analysis (PLS-DA) for the 44 serum  
528 lipids quantified in SARS-CoV-2(n=50) and age and sex matched controls (n=94)  
529 with  $R^2 = 0.944$ ,  $Q^2 = 0.932$  and Accuracy = 1.0 B-I: Histograms of the highest  
530 ranked lipid mediators, PUFA (AA, LA, EPA, DHA), SPMs (17-HDHA, RvD4, LXA4,  
531 LXA5), PGD2, HETEs (5-HETE, 9-HETE, 16-HETE, 19-HETE, 15-HETE), DiHETEs  
532 (5, 15-DiHETEs, 8, 9-DiHETEs), 11,12-EET, DHETs (11, 12-DHET, 14, 15-DHET)  
533 and Endocannabinoids (2-AG, AEA).

534 **Figure 2** Serum concentrations of (A) DHA, (B) 17-HDHA, (C) RvD4 (D) Maresin  
535 2, and (E) 18-HEPE in SARS-CoV-2 (n=50) and age and sex matched control  
536 serum (n=94) stratified by age group. Groups were assessed for normal  
537 distribution using D'Agostino & Pearson test. Significance was assessed using  
538 Kruskal-Wallis test correcting for multiple comparisons using Dunn's test.  
539 \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .

540 **Figure 3.** Correlation analysis of DHA & EPA and relevant down-stream SPM  
541 pathway metabolites (A) 17-HDHA, (B) 14-HDHA, and (C) 18-HEPE in SARS-CoV-  
542 2 (n=50) and age and sex controls (n=94). Data analysed by Spearman's Rho.

543 **Figure 4.** Correlation analysis between AA and down-stream CYP450 metabolites  
544 (A) 5,6-EET, (B) 8,9-EET, (C) 1,12-EET, and (D) 14,15-EET in SARS-CoV-2 and  
545 control groups. Data analysed by Spearman's Rho.

546 **Figure 5.** Serum concentration of significantly altered pro-resolution lipid  
547 mediators A) EPA, B) 18-HEPE, C) DHA, D) 17-HDHA, E) 14-HDHA, F) RvD4, G)  
548 Maresin 2, & H) 14,15-EET based on the anti-spike antibody response (low group  
549  $<0.5$ ,  $n=26$ , (high group  $>0.5$ ,  $n=24$ ) in SARS-CoV-2 patients. Groups were  
550 assessed for normal distribution using D'Agostino & Pearson test. Significance was  
551 assessed using Mann-Whitney test.  $*p<0.05$ ,  $**p<0.01$ ,  $***p<0.001$ ,  
552  $****p<0.0001$ .

553



554 **Table 1.** Concentrations of pro-inflammatory and anti-inflammatory bioactive  
555 lipids quantified in SARS-CoV-2 (n=50) and age and sex matched controls (n=94).  
556 Statistical analysis by Mann-Whitney Test. Where lipids were not detected in  
557 samples, an arbitrary value of 0.001 indicated by \* was used for statistical  
558 analysis.

| Bioactive lipids |                   | Mean Concentration (nM) ± SD |        |   |                   |        |   | P Value |         |
|------------------|-------------------|------------------------------|--------|---|-------------------|--------|---|---------|---------|
|                  |                   | Control (n=94)               |        |   | Sars-COV-2 (n=50) |        |   |         |         |
| AA               | Pro-inflammatory  | µM (±SD)                     | 47.98  | ± | 12.75             | 99.61  | ± | 60.21   | <0.0001 |
| LA               |                   |                              | 307.8  | ± | 109.7             | 213.79 | ± | 108.4   | <0.001  |
| 5-HETE           |                   | nM (±SD)                     | 0.99   | ± | 0.40              | 158.33 | ± | 159.17  | <0.0001 |
| 8-HETE           |                   |                              | 0.81   | ± | 0.57              | 3.52   | ± | 3.32    | <0.0001 |
| 9-HETE           |                   |                              | 0.15   | ± | 0.05              | 16.27  | ± | 19.02   | <0.0001 |
| 11-HETE          |                   |                              | 1.77   | ± | 1.34              | 19.84  | ± | 19.95   | <0.0001 |
| 12-HETE          |                   |                              | 0.001* |   |                   | 162.41 | ± | 137.29  | <0.0001 |
| 15-HETE          |                   |                              | 7.14   | ± | 4.79              | 135.18 | ± | 125.42  | <0.0001 |
| 16-HETE          |                   |                              | 0.20   | ± | 0.05              | 0.22   | ± | 0.08    | 0.4442  |
| 19-HETE          |                   |                              | 0.37   | ± | 0.29              | 188.65 | ± | 199.17  | <0.0001 |
| 20-HETE          |                   |                              | 1.04   | ± | 0.56              | 69.80  | ± | 54.66   | <0.0001 |
| TBxB2            |                   |                              | 21.66  | ± | 20.33             | 63.20  | ± | 80.40   | <0.0001 |
| 11-dihy-TBxB2    |                   |                              | 1.10   | ± | 1.47              | 0.29   | ± | 0.33    | 0.0001  |
| PGE2             |                   |                              | 0.37   | ± | 0.33              | 0.56   | ± | 0.41    | 0.0033  |
| PGD2             |                   |                              | 0.001* |   |                   | 1.12   | ± | 1.34    | <0.0001 |
| LTB4             |                   |                              | 0.52   | ± | 0.72              | 5.30   | ± | 0.67    | <0.0001 |
| 13-oxo-ODE       |                   |                              | 6.82   | ± | 5.45              | 25.85  | ± | 32.33   | 0.0001  |
| 9-oxo-ODE        |                   |                              | 0.85   | ± | 0.96              | 7.51   | ± | 10.28   | <0.0001 |
| 9-HODE           |                   |                              | 6.14   | ± | 3.03              | 225.74 | ± | 308.14  | <0.0001 |
| 13-HODE          |                   |                              | 12.44  | ± | 5.72              | 263.98 | ± | 363.04  | <0.0001 |
| DHA              | Anti-inflammatory | µM (±SD)                     | 36.96  | ± | 17.63             | 39.67  | ± | 27.01   | 0.7135  |
| EPA              |                   |                              | 37.26  | ± | 4.72              | 26.13  | ± | 21.59   | <0.001  |
| 17-HDHA          |                   | nM (±SD)                     | 1.88   | ± | 1.46              | 88.61  | ± | 107.3   | <0.0001 |
| 14-HDHA          |                   |                              | 55.53  | ± | 54.4              | 93.11  | ± | 69.82   | 0.0006  |
| 18-HEPE          |                   |                              | 0.49   | ± | 0.32              | 10.27  | ± | 14.16   | <0.0001 |
| RvD4             |                   |                              | 0.001* |   |                   | 4.11   | ± | 3.94    | <0.0001 |
| Maresin 2        |                   |                              | 0.03   | ± | 0.01              | 0.42   | ± | 0.48    | <0.0001 |
| 5,6-EET          |                   |                              | 0.24   | ± | 0.38              | 0.30   | ± | 0.29    | <0.0001 |
| 5,6-DHET         |                   |                              | 0.38   | ± | 0.21              | 2.35   | ± | 1.73    | <0.0001 |

|             |  |      |   |      |        |   |        |         |
|-------------|--|------|---|------|--------|---|--------|---------|
| 5,6-Ratio   |  | 0.60 | ± | 0.72 | 0.21   | ± | 0.24   | <0.0001 |
| 8,9-EET     |  | 0.21 | ± | 0.21 | 0.74   | ± | 0.88   | <0.0001 |
| 8,9-DHET    |  | 0.22 | ± | 0.07 | 0.47   | ± | 0.32   | <0.0001 |
| 8,9-Ratio   |  | 0.97 | ± | 0.86 | 2.63   | ± | 4.09   | 0.0098  |
| 11,12-EET   |  | 0.56 | ± | 0.77 | 160.95 | ± | 122.47 | <0.0001 |
| 11,12-DHET  |  | 0.53 | ± | 0.16 | 0.60   | ± | 0.32   | 0.315   |
| 11,12-Ratio |  | 1.09 | ± | 1.31 | 363.01 | ± | 407.70 | <0.0001 |
| 14,15-EET   |  | 0.27 | ± | 0.35 | 0.43   | ± | 0.44   | <0.0001 |
| 14,15-DHET  |  | 0.43 | ± | 0.14 | 0.52   | ± | 0.27   | 0.0672  |
| 14,15-Ratio |  | 0.68 | ± | 0.74 | 0.90   | ± | 0.73   | 0.0002  |

559

560


561 **Table 2.** Correlation analysis between concentrations of bioactive lipid with anti-  
562 nucleocapsid & anti-spike antibody response in SARS-CoV-2 (n=50). Data  
563 analysed by Spearman's Rho.

| Bioactive lipids | Correlation Analysis of Lipids vs Antibody binding |              |            |                   |
|------------------|--|--------------|------------|-------------------|
|                  | Anti-Nucleocapsid                                  |              | Anti-Spike |                   |
|                  | R Value  | P Value      | R Value    | P Value           |
| AA               | 0.326  | <b>0.021</b> | 0.352      | <b>0.012</b>      |
| LA               | 0.249  | 0.081        | 0.382      | <b>0.006</b>      |
| DHA              | 0.369  | <b>0.009</b> | 0.337      | <b>0.017</b>      |
| EPA              | 0.419  | <b>0.002</b> | 0.540      | <b>&lt;0.0001</b> |
| 17-HDHA          | 0.269  | 0.059        | 0.537      | <b>&lt;0.0001</b> |
| 18-HEPE          | 0.366  | <b>0.009</b> | 0.410      | <b>0.003</b>      |
| 14-HDHA          | 0.434  | <b>0.002</b> | 0.293      | <b>0.039</b>      |
| RvD4             | 0.211  | 0.142        | 0.449      | <b>0.001</b>      |
| Maresin 2        | 0.282  | 0.055        | 0.343      | <b>0.018</b>      |
| LXA4             | 0.051  | 0.723        | 0.324      | <b>0.022</b>      |
| LXA5             | 0.222  | 0.133        | 0.436      | <b>0.002</b>      |
| 5-HETE           | 0.093  | 0.52         | 0.361      | <b>0.010</b>      |
| 8-HETE           | 0.404  | <b>0.004</b> | 0.419      | <b>0.002</b>      |
| 9-HETE           | 0.27   | 0.058        | 0.469      | <b>0.001</b>      |
| 11-HETE          | 0.279  | <b>0.05</b>  | 0.464      | <b>0.001</b>      |
| 12-HETE          | 0.231  | 0.106        | 0.084      | 0.563             |
| 15-HETE          | 0.259  | 0.069        | 0.407      | <b>0.003</b>      |
| 16-HETE          | 0.245  | 0.097        | 0.045      | 0.756             |
| 19-HETE          | 0.138  | 0.344        | 0.314      | <b>0.028</b>      |
| 20-HETE          | 0.234  | 0.101        | 0.099      | 0.494             |
| TBxB2            | -0.26  | 0.071        | -0.052     | 0.722             |
| PGE2             | 0.049  | 0.744        | 0.275      | 0.056             |
| PGD2             | 0.113  | 0.445        | 0.283      | 0.052             |
| LTB4             | -0.041   | 0.776        | 0.326      | <b>0.021</b>      |
| 5,6-EET          | 0.357  | <b>0.011</b> | 0.271      | 0.057             |
| 5,6-DHET         | 0.024  | 0.867        | 0.310      | <b>0.029</b>      |
| 5,6-Ratio        | 0.243  | 0.089        | -0.018     | 0.904             |
| 8,9-EET          | 0.099  | 0.494        | 0.185      | 0.198             |
| 8,9-DHET         | 0.063  | 0.663        | -0.104     | 0.474             |
| 8,9-Ratio        | 0.064  | 0.664        | 0.164      | 0.257             |
| 11,12-EET        | 0.239  | 0.093        | 0.084      | 0.564             |
| 11,12-DHET       | 0.109  | 0.452        | -0.041     | 0.779             |
| 11,12-Ratio      | 0.15   | 0.297        | 0.114      | 0.431             |
| 14,15-EET        | 0.302  | <b>0.033</b> | 0.334      | <b>0.018</b>      |
| 14,15-DHET       | 0.023  | 0.874        | -0.194     | 0.178             |
| 14,15-Ratio      | 0.339  | <b>0.016</b> | 0.443      | <b>0.001</b>      |
| 13-oxo-ODE       | 0.202  | 0.169        | 0.447      | <b>0.002</b>      |
| 9-oxo-ODE        | 0.243  | 0.154        | 0.482      | <b>0.003</b>      |
| 9-HODE           | 0.265  | 0.063        | 0.505      | <b>0.0002</b>     |
| 13-HODE          | 0.268  | 0.059        | 0.488      | <b>0.0003</b>     |
| AEA              | 0.017  | 0.907        | -0.216     | 0.131             |
| PEA              | -0.071   | 0.626        | -0.083     | 0.567             |
| OEA              | 0.063  | 0.666        | -0.060     | 0.679             |


564

565


566 Figure 1.




568 Figure 2.



570 Figure 3.



572 Figure 4.



574 Figure 5.

